SCHEMBL2448633

SCHEMBL2448633

COc1ccc2nc3cc(Cl)ccc3c(Cl)c2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.68
PHLPP2 Q6ZVD8 2/20 0.56
ADORA2A P29274 1/20 0.56
CYP19A1 P11511 1/20 0.56
KMT2A Q03164 3/20 0.55
TDP1 Q9NUW8 3/20 0.55
MEN1 O00255 2/20 0.55
MBNL1 Q9NR56 1/20 0.54
APP P05067 2/20 0.51
MAPT P10636 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
USP2 O75604 2/20 0.50
TP53 P04637 2/20 0.50
CYP3A4 P08684 2/20 0.50
CASP1 P29466 2/20 0.50
CASP7 P55210 2/20 0.50
HBB P68871 2/20 0.50
HSD17B10 Q99714 2/20 0.50
AURKA O14965 1/20 0.50
AURKB Q96GD4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31038657 1.00 KDM4E (0.68) KDM4EPHLPP2ADORA2ACYP19A1KMT2A
SCHEMBL30603139 1.00 KDM4E (0.68) KDM4EPHLPP2ADORA2ACYP19A1KMT2A
SCHEMBL14126140 0.95 KDM4E (0.62) KDM4EPHLPP2ADORA2ACYP19A1KMT2A
SCHEMBL31500228 0.95 KDM4E (0.61) KDM4EPHLPP2ADORA2ACYP19A1KMT2A
SCHEMBL20535915 0.94 KDM4E (0.62) KDM4EPHLPP2ADORA2ACYP19A1KMT2A
SCHEMBL11194565 0.92 KDM4E (0.61) KDM4EPHLPP2ADORA2ACYP19A1KMT2A
SCHEMBL9594726 0.92 KDM4E (0.57) KDM4EPHLPP2ADORA2ACYP19A1KMT2A
SCHEMBL12285138 0.88 KDM4E (0.55) KDM4EKMT2AMEN1APPHSD17B10
SCHEMBL31500219 0.87 KDM4E (0.53) KDM4EPHLPP2ADORA2ACYP19A1KMT2A
SCHEMBL6778691 0.86 APP (0.69) KDM4EPHLPP2ADORA2ACYP19A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116715602-A Fluorenyl oxalyl diamine compound, derivative and application thereof 华东理工大学 2023-09-08 CN claimed
EP-3049083-A2 COMPOUNDS FOR INHIBITION OF UNREGULATED CELL GROWTH Godavari Biorefineries Ltd. (IN) 2016-08-03 EP claimed
US-20160214941-A1 Compounds for lnhibition of Unregulated Cell Growth GODAVARI BIOREFINERIES LIMITED (IN) 2016-07-28 US claimed
WO-2015044960-A2 COMPOUNDS FOR INHIBITION OF UNREGULATED CELL GROWTH GODAVARI BIOREFINERIES LIMITED (IN) 2015-04-02 WO claimed
WO-2004061416-A2 METHODS FOR ATTACHING MOLECULES GENORX, INC. (US) 2004-07-22 WO claimed
US-20040048241-A1 Methods for attaching molecules GENORX, INC. 2004-03-11 US claimed
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 US claimed
US-5886185-A ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS DEVELOPMENT CENTER FOR BIOTECHNOLOY (TW) 1999-03-23 US claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO claimed
US-12247246-B2 Identification of inhibitors of TcpC and TIR NADase activity WASHINGTON UNIVERSITY (US) 2025-03-11 US disclosed
US-20230301984-A1 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-09-28 US disclosed
US-20230303618-A1 TRIPTOLIDE CONJUGATES AND USES THEREOF REYOUNG CORPORATION (US) 2023-09-28 US disclosed
US-20230303618-A1 TRIPTOLIDE CONJUGATES AND USES THEREOF REYOUNG CORPORATION (US) 2023-09-28 US disclosed
CN-116715602-A Fluorenyl oxalyl diamine compound, derivative and application thereof 华东理工大学 2023-09-08 CN disclosed
EP-0436582-A1 PHOSPHOROTHIOATE AND NORMAL OLIGODEOXYNUCLEOTIDES WITH 5'-LINKED ACRIDINE THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) 1991-07-17 EP disclosed
EP-0406309-A1 OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES THE UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1991-01-09 EP disclosed
WO-1990003383-A1 PHOSPHOROTHIOATE AND NORMAL OLIGODEOXYNUCLEOTIDES WITH 5'-LINKED ACRIDINE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) 1990-04-05 WO disclosed
WO-1989009221-A1 OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1989-10-05 WO disclosed
US-3948920-A New anti-malarial agents AKTIEBOLAGET ASTRA (SW) 1976-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247246-B2 Identification of inhibitors of TcpC and TIR NADase activity NADK, NAPRT, TIPARP KDM4E 3114/4885PHLPP2 3053/4885ADORA2A 4308/4885
US-20230301984-A1 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION ALDH1A2, PDE6D, PDE6C KDM4E 3316/4885PHLPP2 1530/4885ADORA2A 2888/4885
US-20160214941-A1 Compounds for lnhibition of Unregulated Cell Growth MKI67, LYAR, CCNI KDM4E 2994/4885PHLPP2 2546/4885ADORA2A 3702/4885
US-20230303618-A1 TRIPTOLIDE CONJUGATES AND USES THEREOF TLR9, XIAP, ENPP2 KDM4E 2714/4885PHLPP2 816/4885ADORA2A 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.